Prostaglandins in glaucoma

Document Type : Original Article(s)

Authors

1 Assistant Professor, Department of Ophthalmology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

The prostaglandin-related topical medications include latanoprost, unoprostone, travoprost, and bimatoprost. They are the new class of glaucoma medications. Prostaglandin analogs reduce intraocular pressure (IOP) by improving uveoscleral outflow primarily by altering the extracellular matrix. These prostaglandin-related agents or hypotensive lipids have a potent ocular antihypertensive agent when given once daily, with the exception of unoprostone, which is prescribed twice a day. Monotherapy with prostoglandins can reduce IOP levels by 29-32% over 1-12 months. Prostaglandins are quickly becoming important first-line agents in the treatment of glaucoma. They are well-tolerated and lack significant systemic side effects. They have the added benefit of once daily dosing. At high doses, these produce ocular inflammation and hypertension, but in smaller amounts, they reduce IOP. Prostaglandin analogs are contraindicated in any patient who is allergic or sensitive to these drugs, those with multiple risk factors, with iritis, herpes simplex keratitis or in the immediate postoperative period following intraocular surgery and patients with a history of uveitis and ocular herpes infection.     Prostaglandin, glaucoma Key words:  
Journal of Isfahan Medical School
Volume 26, Issue 91 - Serial Number 91
September and October 2009

Files

History

  • Receive Date: 07 November 2010
  • Revise Date: 26 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics